The aggressiveness of gliomas is driven by a complex interplay of genetic, epigenetic, and microenvironmental factors: Mutations in IDH1/2, TP53, and EGFR are strongly associated with tumorigenesis and progression. This evidence concerns the gene TP53 and central nervous system cancer.